Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with, or are suspected to have, a type of adult brain tumour called an adult-type diffuse glioma (including glioblastoma, astrocytoma, or oligodendroglioma, as classified by World Health Organization guidelines)
- People who are willing to provide tumour tissue samples — either already stored from a previous biopsy or surgery, or newly collected
- People aged 20 years or older
- People with a life expectancy of more than 3 months
- People who fully understand the study plan and are willing to attend regular follow-up appointments
- For Arm 1 only: People who are within 2 months of having surgery to remove their primary tumour
- For Arm 2 only: People who have had their primary tumour fully removed and have tumour tissue samples available for testing
- For Arm 3 only: People who have had their primary tumour fully removed, have paired tissue samples from both the original and a returned tumour available for testing, and whose tumour test results suggest a specific genetic pattern called "IDH wild-type" (confirm with trial site)
Who may not be able to join:
- People whose brain tumour has been diagnosed as, or is suspected to be, a type other than an adult-type diffuse glioma — for example, pediatric-type diffuse gliomas or circumscribed astrocytic gliomas
- People who are unable to provide a complete medical history
- People who do not agree to provide stored tumour tissue samples
- People who are unlikely to follow the study requirements as needed (confirm with trial site)
- People who have another cancer that is currently progressing or has needed active treatment within the last 3 years — however, people who have had certain skin cancers (basal cell or squamous cell carcinoma of the skin) or early-stage localised cancers (such as cervical carcinoma in situ) that were treated with the aim of curing them are not excluded on this basis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kwang-Yu Chang, MD,PhD, National Health Research Institutes, Taiwan
Phone: +886-3-7206166
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the genetic profiles in brain tumor patients in Taiwan.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.